hiv/aids in children
DESCRIPTION
HIV/AIDS in children. Plan of the lecture. The etiology of HIV infection, history of the HIV discovery HIV infection e pidemiology, pathogenesis HIV infection d iagnostic criteria HIV infection Antiretroviral Therapy HIV infection prevention. HIV - infection. AIDS. - PowerPoint PPT PresentationTRANSCRIPT
1
HIV/AIDS in children
2
Plan of the lecture
The etiology of HIV infection, history of the HIV discovery
HIV infection epidemiology, pathogenesis HIV infection diagnostic criteria HIV infection Antiretroviral Therapy HIV infection prevention
3
HIV: Human Immunedefficiency Virus
a retrovirus, its genetic material, RNA, while replicating change the structure of host cell DNA
AIDS: Aquired Immune Defficiency Syndrome
HIV-infection AIDS
8-10 years in average* *without treatment
4
HIV infection - a chronic infectious disease that develops because of infection with human immunodeficiency virus (HIV) and is characterized by progressive immune system
damage
AIDS - a terminal (final) 4th stage of the HIV infection course as the result of the human immune system destruction by the virus (HIV), and loss of human capacity to resist infections and diseases
5
History of HIV discovery History of HIV discovery Spring 1981 - + 5 patients with malignant pneumocystis pneumonia
6
History of HIV discoveryHistory of HIV discovery winter 1980-81 -- first patients with Kaposi sarcoma, malignant form in the United States
7
RR. . GALLOGALLO LL. . MontMontoonnaeae
They They had had opened HIVopened HIV
8
Human immunodeficiency virus 109 new viruses
Appears every day reverse
transcriptase makes “errors" at each transcription
there significant number mutations due large number of errors, but on undetectable level
9
Etiology
HIV - Т- lymphotropic retrovirus of ІІІ type RNA-containing, cells-targets – DNA-соntaining (helpers
T-lymphocytes) Enzymes: reverse transcriptase (revertase), protease Specific markers – p24, gp41, gp120, gp160 Genome of the virus include 3 structure genes (as all
retroviruses) and 6 regulatory genes (increase replication, activate of virus protein structure synthesis)
10
HIV BIOLOGICAL CHARACTERISTICS - HIGH genetic variability (up to 104 -105
mutations / gene / every replication cycle, predominantly in the gene gp120)
Resistance of HIV in an infected organism - Rapid development of drug resistance - Modified tropism of HIV at different stages
of disease - Difficulty in creating an effective vaccine
11
Stability of the virus in the Environment When drying the cell cultures will kill the virus at t˚ +23
+27 ˚C for 3-7 days. In liquid at a temperature of +23-27 C - within 15 days, In the blood for transfusion is going through the years,
and in the frozen serum - activity persists up to 10 years.
HIV dies quickly when using disinfectants, UV radiation, when heated above 56 C loses activity after 30 minutes.
HIV loses activity under the influence of protective enzymes of saliva and sweat.
12
Epidemiology Source – sick and carrier (contagious during all life) Mеchanism of transmission – contact (wound), vertical Ways of transmission: natural: sexual (homosexuals – 1-3 %, females – 0.6 %,
males – 0.09 %) vertical (transplacentar – 15-20 %, childbirth – 50-70 %,
during breast feeding – 20-30 %) artificial: parenteral manipulations and drug using – 30
%, blood recipients – 100 %, transplantation of organs and tissues, artificial abortion – 100 %
professional: infection of medical personal – 0.1-0.4 %. Intrahospital outbreaks.
13
WHAT BE FOR TRANSFER HIV?
HIV +
HIV
Ways of transmission: - sexual,
-Through the blood, - From mother to child
HIV-
Factors transfer (Biological fluids with
high HIV-content)
sperm Vaginal -
secret blood milk
When absence although one of these factors the chain will torn and infection is not developed
14
Estimated risk of transmission HIV from mother to child (in the absence of any interventions)
During pregnancy, 5-10% During childbirth 10-20% When breastfed 5-20%
15
HIV is not transmitted:
When insect bites (mosquitoes, fleas, lice, beetles, flies, etc.)
With saliva, sweat, urine, feces, sputum, discharge from the nose, tears, vomitus (if there is no visible admixture of blood)
Household contact
16
Transmission has not been proved during puncture Cerebrospinal Synovial Pleural Peritoneal Pericardial Amniotic
17
Biological fluids, which contacted you may be infected HIV:
Blood and any liquid with a visible admixture of blood
Sperm Vaginal Discharge Culture containing HIV
18
Treated with care require:
any biological fluid, if it is difficult to determine what kind of fluid
Any excised (or deleted by other means, in vivo or post-mortem) human tissues and organs
tissues and organs of experimental animals infected with blood-borne infections;
any cuts of unknown origin.
19
Trans-dermal contact Needlesticks cut with a sharp object
Contact with biological materials on mucous membranes or broken skin
Contact intact skin with blood, biological tissues or fluids for a long time or over a large area
Contacts associated with the risk of infection:
20
Assessment of infection risk contact with HIV-infected blood through the
damaged skin, 0,3% (0,2 - 0,5%) getting blood on the mucous membranes -
0,09% (0,006-0,5%) contact with intact skin - the risk is not
detected contact with body fluids - the risk is not
detected
21
The risk of transmission of the virus in trauma with a sharp instrument contaminated with body fluids of an infected patient
Patient Risk
HIV + 0,3%
HBsAg+
HBeAg+
3%
30%Hepatitis C 2%* Невакцинированные медработники
22
Ways of infection when professionally contact
Ways of infection when professionally contact
Інфікування при пораненні 90
Інфікування через слизові 10
90%10%
From: CDC. MMWR 1998;47:No. RR-7.
23
Pathogenesis of HIV infection in humans Infection occurs through close contact with blood or
other body fluids containing the virus in sufficient quantities for infection (semen, vaginal secretions, breast milk)
In the penetration of the virus in the body involved mucosal dendritic cells
The virus rapidly infects activated CD4 lymphocytes near the gate of infection and reaches with them the regional lymph nodes
Following this, HIV is spread through the body with blood and lymph
24
Pathogenesis of HIV infection The virus is detected in the blood and lymph nodes, in
long-living lymphocytes it is contained in a latent form, which makes it impossible to completely eliminate.
Persistent failure of the lymphatic system occurs within 48 hours In contact with infected blood or other body fluids should be as
soon as possible to take preventive measures (optimal in the first hours after contact)
For some groups of patients it is characterized by depression of the immune system and a more rapid progression of infection. These include:
Infants Individuals with defects in the immune system
25
The life cycle of HIV and a target for drugs
26
27
HIV and the immune system HIV uses mostly CD 4 cells to reproduce CD 4 cells - contain CD 4 receptors on their
surface CD 4 receptors are located on the surface of
many cells, but mainly on the T 4 lymphocytes (T helper)
The shell of the virus contains a molecule that helps him connect to the CD4 receptor and to penetrate into the cell
28
A “Window" Period
АТ
29
HIV and the immune system"Window" Period
This is the time needed to accumulate in the body a sufficient number of antibodies to HIV, which is determined by laboratory
tests
(3 months - in 99%)
30
DEVELOPMENT OF HIV INFECTION
Stages:
Acute viral infection
The latent period of asymptomatic carriers
HIV infection (4th stage - AIDS)
31
Development of the diseaseDevelopment of the disease 2004 WHO Classification2004 WHO Classification
Clinical stage I
Asymptomatic Generalized lymphadenopathy
32
Development of the diseaseDevelopment of the disease 2004 WHO Classification2004 WHO Classification
Clinical stage II
Weight loss is less than 10% of the original
Mild skin and mucous damages Shingles (herpes Zoster) Recurrent upper respiratory tract infection
33
Herpetic stomatitis (Canker Sore)
34
Herpes simplex
35
Rerccurent Herpes labialis (Cold Sore)
36
Herpes Zoster
37
Development of the diseaseDevelopment of the disease 2004 WHO Classification2004 WHO Classification
Clinical stage III
Weight loss is more than 10% of the original Diarrhea of unknown etiology Prolonged fever of unknown etiology Oral Candidiasis Oral hairy leukoplakia Pulmonary tuberculosis Serious bacterial infection
38
Oral Candidiasis (thrush)
39
Oral Candidiasis (thrush)
40
Leukoplakia
Oral hairy leukoplakia
41
Development of the diseaseDevelopment of the disease 2004 WHO Classification2004 WHO Classification
Clinical stage IV (AIDS) HIV cachexia PCP Toxoplasmosis Kaposi’s sarcoma Lymphoma Other AIDS indicator disease
42
Kaposi sarcoma
43
Mouth cancer
44
Condyloma acuminata (Human Papylomavirus infection)
45
Lichen planus
46
Indicators that determine the stage Indicators that determine the stage
of HIV infection:of HIV infection: Clinical
Immunological Virological
Virus load
Number and % CD4/8
Total number of lymphocytes
Opportunistic infections and AIDS - Indicator diseases
47
Examples of the diagnosis by WHO classification: HIV infection, the second clinical stage,
without significant immunosuppression HIV infection, the fourth clinical stage,
severe immunosuppression.
48
Opportunistic infections
HIV slowly destroys CD 4 cells during many years of infection
When the number of CD 4 cells decreases germs of infectious diseases can easily penetrate into the body, causing the development of opportunistic infections (germs that do not cause pathological process in people with normal immunity)
49
Laboratory studies Serological methods for diagnosis of HIV
infection. ELISA (routine serological test). Immune blot method (Western blot). Determination of antigen-R24. Determination of R24-
antigen in serum implies the presence of HIV in the body. It appears in the blood, as in the early stages, and in progression of HIV infection.
Molecular genetic and virological research methods
HIV DNA PCR HIV RNA PCR Getting HIV culture
50
Diagnosis of HIV-infected child under 18 months: age - under 18 months + antibodies to HIV determined in serum (ELISA
and immune blot) or a child was born by HIV-infected women +
child has two positive results, done by one of the following methods: PCR DNA a culture of HIV definition of R24 antigen.
51
Diagnosis of HIV-infected child older than 18 months: age - 18 months and older + antibodies to HIV determined in serum (ELISA
and immune blot) + a child was born by HIV-infected women or the child received blood or the child received
the virus by other means (including sexually).
52
Diagnosis of HIV perinatal contact (status is uncertain): age - under 18 months + antibodies to HIV determined in serum
(ELISA and immune blot) or a child was born by HIV-infected women.
53
HAART: Highly active Antiretroviral Therapy (or triple combination therapy)
The only effective way to suppress the virus
Use one or two drugs leads to the fact that the virus becomes resistant (resistance)
54
Механизм действия АРВпрепаратов
ОТ
ПРОВИРУС
ПРОТЕИНЫРНК
РНК
ОТ
РНК
РНК
ДНК
ДНК
ДНК
Протеаза
Обратнаятранскриптаза
Фузион
Интеграза
ИнгибиторыпротеазыSQVRTVIDVNFVLPV
1 НуклеозидныеингибиторыобратнойтранскриптазыZDV, ddI,d4T, 3TC, ABC,TDF, 2 Не-нуклеозидныеингибиторыобратнойтранскриптазыNVP, EFV
ИнгибиторыслиянияEFV (T20)
РНК
от
РНК
ДНКот
ДНК
ДНК ПРОВИРУС
РНК
РНК
ПРОТЕИНЫ
55
NNRTI
’’8787 ’’9191 ’’9292 ’’9494 ’’9595 ’’9696 ’’9797 ’’9898 ’’9999 ‘‘0000’’8888 ’’8989 ’’9090
RTIRTI
PIPI
RetrovirRetrovir
NorvirNorvir
InviraseInvirase
CrixivanCrixivan
FortovaseFortovase
KaletraKaletraViraceptViracept
ZiagenZiagen
CombivirCombivir
VidexVidex
HividHivid
ZeritZerit
EpivirEpivir
TrizivirTrizivir
Rescriptor
SustivaViramune
’’0101
VireadViread
EmtrivaEmtriva
FuzeonFuzeon
ReyatazReyataz
‘‘0202 ‘‘0303’’9393
AgeneraseAgenerase
LexivaLexiva
‘04
History ARV drugs From 1987 to 1995. To use the 4 ARV drug Class NRTIs. In second half of the 90 - x years started used NNRTI drugs. Since 1995 started application protease inhibitors (PI).
56
Effects of ARV therapy
The purpose of ARV therapy: Improve the quality of life Prolong life
ARVs do not cure people of HIV infection Lifetime administration of drugs Commitment (attitude and punctuality
admission)
57
Effects of ARV therapy
HIV ceases to be a death sentence for people
and becomes a "chronic" disease
which - subject to constant use of the drugs - you can live, learn, work, create a family, having children.
58
Problems associated with ARV drugs
Limited access to ARV drugs Long-term (life), which requires strict regime of
time reception (commitment) - necessity of uninterrupted supply of ARV drugs
The presence of side effects that reduce quality of life of the patient
Difficulties with the quality monitoring of the patient and his viral load
Fear of disclosure of HIV status
59
Benefits Benefits antiretroviral therapy antiretroviral therapy Ability to reduce viral load
Ability to reduce the risk of vertical transmission of HIV from mother to child
Ability to extend the life of a person with AIDS
60
The first ART series schemes
recommended in Ukraine Schemes based on NRTI: 1 NNRTI + 2 NRTIPreference is recommended to:
EFV + AZT / ZTS
EFV + TDF * + FTC * (or ZTS)
Possible use, but not a full-fledged alternative: NVP + AZT / ZTS
Schemes based on PI: 1 PI + 2 NRTI
Preference is recommended to:
LPV / rtv + AZT / ZTS
LPV / rtv + TDF + FTC (or ZTS)
Possible use in case intolerance to LPV / rtv, but not a full-fledged alternative: NFV + AZT / ZTS
61
Dosing regimens of antiretroviral drugs for adults
and adolescents Nucleoside / nucleotide reverse transcriptase inhibitors (NRTI)
Zidovudine (AZT) 300 mg 2 times a day
Stavudine (d4T) 40 mg 2 times a day (30 mg 2 times a day, with weight <60 kg)
Lamivudine (ZTS)
150 mg 2 times a day
Didanozine (ddI) 200 mg 2 times daily or 400 mg 1 per day (in the application of capsules)
(250 mg 1 per day, with weight <60 kg or reception in conjunction with TDF)
Abacavir (FAA) 300 mg 2 times a day
62
Nucleoside / nucleotide reverse transcriptase inhibitors (NRTI)
Emtriсytabine (FTC) 200 mg 1 per day
Tenofovir (TDF) 300 mg 1 per day
Combination drug AZT / ZTS
300 mg/150 mg 2 times a day
Combination drug AZT / ZTS / ABC
300 mg/150 mg/300 mg 2 times a day
63
Nonnucleoside reverse transcriptase inhibitors (NNRTI) Efavirence (EFV) 600 mg 1 per day (in
combination with rifampicin 800 mg 1 per day)
Nevirapine (NVP) 200 mg 1 time per day during the first 14 days
than - 200 mg 2 times a day
64
Protease inhibitors (PI)
Lopinavir / ritonavir (LPV / rtv)
400 mg/100 mg 2 times a day (if granted in conjunction with ifavirentsom or Nevirapine, a dose increase to 533 mg/133 mg 2 times a day)
Nelfinavir (NFV) 1250 mg 2 times a day
Saquinavir / ritonavir (SQV / rtv)
1000 mg/100 mg 2 times a day
Atasanavire / ritonavir (ATV / rtv)
300 mg / 100 mg 1 per day
Fosamprenavir / ritonavir (FPV / rtv)
700 mg/100 mg 2 times daily or 1400 mg/200 mg 1 per day
65
Other treatment Immune correction – interleukin-2 (roncoleukin), tactivin,
timalin, inerferons, immunofan, splenin, galavit, specific (monoclonal) antibodies, transplantation of thymus аnd bone marrow
Treatment of opportunistic infections protozoal – Trymetoprim/sulfametoxazolum,
pirimethamin/sulfamеthоxаzоlum, metronidazolum, pentamedinum; mycosis – amphotericin В, kеtоkоnаzоlum, flukonazolum; herpetic infection – acyclovir, valtrex, zovirax, interferon, laferon; CMV-infection – gancyclovir, foskarnet; bacterial – antibiotics – macrolids, fluorqinolons, karbapenems,
cephalosporins, aminoglycosides) Anti tumor remedies Pathogenetic and symptomatic therapy
66
Vaccination schedule for children born by HIV
positive women, HIV infected and AIDS patients BCG Contraindicated
DPT / DT Ply on the calendar
Hepatitis B Ply on the calendar
Hib Ply on the calendar
MMR Ply on the calendar
Inactivated (IPV) Ply on the calendar
Oral, live (OPV) Contraindicated
Rabies Only postcontact prevention
Influenza Every autumn, repeated annually
67
Prevention of HIV Transmission
68
Approaches to HIV prevention
Removing risk Reducing risk
69
Mandatory testing of blood and special processing of blood products.
Prevention of infection in health care and beauty parlors (tools for injection and manipulation by contact with blood).
Prevention of occupational infection with HIV (medical personnel, etc.)
Methods of parenteral infection prevention
70
Fighting HIV infection in health care Use of disposable instruments Handwashing Use of personal protective equipment: gloves,
goggles, apron, and shoe covers Organization of activities in case of emergency When drawing blood and conducting laboratory
and diagnostic studies of blood and other body fluids of any patient should be treated as potentially dangerous in terms of HIV infection
71
Guidelines reduce the risk of HIV
transmission from mother to child Antiretroviral prophylaxis for mother and
child Planned (elective) Caesarean section Artificial feeding Also recommended:
Prevention or treatment by STDs Noninvasive procedures
72
Post-Exposure Prophylaxis of HIV infection
73
First aid for exposure to HIV through injury
Immediately! Wash the damaged area with soap and water Rinse it under running water wash the surface by disinfectant or gel for hand washing
NOT! alcochol Iodine Squeezing or rubbing Suck blood
74
First aid for exposure to HIV through spraying
Immediately! Wash the damaged area with soap and water wash the surface by disinfectant or gel for hand washing 2-4% chlorhexedin gluconate solution Rinse eyes with water
NOT! alcochol Iodine bandage
75
PEP (Post Exposure Prevention) . Protocol. ARVs
(If the result of HIV testing in an employee-negative, and the patient's positive): A. Beginning in the early hours after exposure (Required no
later than the first 72 hours). B. Assign triple ART course for 4 weeks: Two drugs - a combination of zidovudine and lamivudine: Zidovudine - 300 mg every 12 hours, and lamivudine - 150 mg orally every 12 hours
The third drug: lopinavir / ritonavir - 400/100 mg orally every 12 hours (the
drug of first choice) Alternative PI but less preferred:
saquinavir / ritonavir - 1000/100 mg orally 2 times a day.
76
Epidemic situation
77
78
79
80
Statistics 6-7 thousand young people infected with HIV every day The rate of infection in the world 4.5 people / minute 50% of new infections - young people aged 15-24 years 50% of the total number of PLHIV - Women 13.1 million children worldwide have been orphaned by
HIV, to 2010, the number of orphans will reach 25 million man
At the beginning of the HIV epidemic was assumed that the victims of the epidemic by 2006 will be 1.7 million people
95% of People Living with HIV live in developing countries
81
Characteristics of the epidemic Struck the younger generation. In the world
- more than one-third of people aged 15 to 24 years living with HIV / AIDS
Most people do not know about that are infected with this virus
Many millions know nothing or almost nothing about HIV to protect themselves from infection
82
Level transfer HIV from mother to child (%) for Ukraine
40%27%
10,00 %
10,00 %
8.20%
7.70%
7,00 %
0% 5% 10% 15% 20% 25% 30% 35% 40%
2000
2001
2002
2003
2004
2005
2006
83
Thank you for your attention!